Connect with us

Business

Can You Ask Your Doctor for Medical Marijuana Instead of Painkillers and Opioids?

Published

on

It is reasonable to be skeptical about prescribed pain medication. The opioid crisis in America keeps on taking scores of lives, as a lot of other people are living with being subtly dependent on medication for pain.

If you have injuries or require surgery, you will most likely experience pain. You might also not want to deal with a pain medication that can be addictive and might wish to reject it when it’s offered. As has been previously reported, marijuana can serve as an excellent substitute for opioids. But what are the chances that your doctor will prescribe weed for you rather than painkillers?

Professionals in the healthcare sector actually can’t tell you to use weed as THC in the cannabis is still classified as a Schedule 1 drug by the federal government. In plain terms, your physician can’t simply throw out your prescription for opioids and give you a fresh prescription for medical cannabis. However, depending on the state you find yourself in, the physician might be able to help you recuperate by making use of cannabis as a medical treatment

Be Truthful with Your Doctor

You stand to gain nothing from not being straight or attempting to lie to your doctor. They can easily tell when you are lying as they have a wealth of knowledge and experience dealing with patients. If you want to use medical marijuana in place of another pain medication, simply make your case to them. Talking to your doctor about medical marijuana may seem awkward at first, but it is worth a try to see what they think.

It’s no secret the present opioid problem in the United States is terrifying to many people, especially seniors.  A doctor is probably going to be a lot more open with a patient that is truthful about preferring to use the marijuana route instead of using opioids. If you have any fears concerning the negative side effects of opioids or the danger they pose, speak up. This will not ensure you get a card for medical marijuana, but it gives room for discussion on other treatments.

Being truthful about your cannabis intake can help you as well before surgery and during treatment. You have to let your doctor know if you are using cannabis and, if so, how much. “To know what medicines to use and how often, you also need to let your doctor know in advance how often you use and how much you use cannabis,” Harvard said.

Make Your Findings Realistic

As you prepare to ask your doctor to approve cannabis prescriptions to alleviate your pain, you should sound educated on the subject,. This can be a difficult task to carry out, as medical research on cannabis continues to be difficult because it is still illegal federally. This absence of research is part of what hinders doctors and organizations from completely accepting medical cannabis today.

For example, the CDC (Centers for Disease Control and Prevention) has stated that “although pain control is one of the most general reasons people report medical cannabis use in the U.S., there is little evidence that cannabis is effective in treating various types of chronic or acute pain.” This suggests that approaching your physician with exploration, information, and sufficient defense for your wanting to use cannabis rather than any other pain relief drug is a good system to help prevent your physician from telling you that the information to back it up just is not sufficient.

Doctors are very knowledgeable but keep in mind that medical cannabis and its merits are still a very new science, and only some medical professionals will have current information about all the latest developments.

Take Your Physician’s Advice

After all is said and done, you have to remember that your physician is offering you an informed opinion, and you ought not to shrug it off and insist that it is an MMJ card or nothing. Treatment plans and medical opinions should be followed to avoid taking unnecessary risks. Take this advice seriously if your doctor does not recommend cannabis as an alternative to painkillers.

Have in mind that even if your physician is not in support of your preference to make use of medical cannabis, you might go and look for another opinion. After all, NORML said that more than half of medical professionals believe that you can use cannabis medically.

However, if you notice that a second opinion says no to medical cannabis, you should listen to their advice. In any case, cannabis is not a cure for everything. Some medical issues require certain treatment plans that do not include marijuana.

Some Doctors Welcome It

One of the doctors authorizing patients for medical marijuana in Missouri, Dr. Patricia Hurford, was skeptical about the merits of medical cannabis for a long time. Hurford said that she felt it was probably a gateway drug, or that there just wasn’t adequate science to support its use.

Hurford is also practicing in Illinois. After the state-approved medical marijuana in 2013, she began to look at things from a different angle. Her patients often suffered from chronic pain and asked her about its application. Hurford eventually agreed to try marijuana, after the normal drug therapies failed to help one patient. Hurford stated that she could not manage their pain with either opioids or non-opioids. After this patient was certified, she saw a dramatic change in the quality of the patient’s life.

For Hurford, it is crucial to investigate how the use of potentially addictive analgesics can be reduced among her patients. She started by saying that with the number of complications she has with opioids and the number of patients who fall into opioid addiction, she finds marijuana to be a much safer and more useful alternative.

Although it is not required by the state, Hurford ensures patients get a list of likely side effects and dangers of marijuana use, such as lung diseases, allergic reactions, and memory problems.

Bottom Line

Medical cannabis is a relatively new concept that does not have substantial scientific evidence to make it a sure cure or a perfect alternative to painkillers. Although there have been cases here and there that support the claim that medical marijuana is a better way to cure pain, some doctors will not give in to the trend based on hearsay alone due to the fear of cannabis as a drug being a gateway drug, meaning patients can easily get hooked on it.

Source: https://cannabis.net/blog/opinion/can-you-ask-your-doctor-for-medical-marijuana-instead-of-painkillers-and-opioids

Business

Alleged Crores Pharma Scam Mastermind Arrested from Surat

Published

on

By

After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.

Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.

Fake Business Deals and Dishonoured Cheques Used in Fraud

Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.

In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”

Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.

Multiple Identities and Repeated Fraud Pattern

Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.

Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.

Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.

Multi-State Surveillance Leads to Arrest in Surat

A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.

Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.

Growing Threat of Corporate Identity Fraud

The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.

Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.

Experts Urge Stronger Due Diligence in High-Value Transactions

Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.

Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.

Continue Reading

Business

EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices

Published

on

By

A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.

Investigation Under Digital Markets Act Gains Momentum

The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.

Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.

Industry Groups Demand Swift Action

Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.

Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.

In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.

Google Denies Allegations

Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.

However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.

Potential Billion-Euro Penalties

If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.

Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.

Wider Implications for Big Tech

The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.

A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.

As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.

Continue Reading

AI & Technology

Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations

Published

on

By

Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).

The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.

Trial Push Despite Multi-Million Euro Settlement

The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.

Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.

A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.

Allegations of VAT Evasion Through Marketplace Sellers

At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.

Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.

Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.

Italian Government Named as Affected Party

In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.

Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.

Multiple Investigations Add to Pressure

The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.

Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.

In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.

Amazon Denies Allegations

Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.

Broader Impact on Europe’s Digital Economy

If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.

With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News